在抑郁症中使用-葡萄糖共载体-2 抑制剂
David T Liebers1, Wataru Ebina, Dan V Iosifescu
1From Department of Psychiatry, New York University Grossman School of Medicine (Drs. Liebers and Iosifescu); Division of Hematology and Medical Oncology, New York University Grossman School of Medicine (Dr. Ebina); Clinical Research Division, Nathan Kline Institute for Psychiatric Research, Orangeburg, NY (Dr. Iosifescu).
Harvard review of psychiatry
|July 12, 2023
概括
需要新的抑郁症治疗方法. 这项研究探讨了SGLT2抑制剂如何通过诱导生成来改善抑郁症患者的大脑能量代谢和情绪.
科学领域:
- 神经科学是一个神经科学.
- 代谢障碍 代谢障碍 代谢障碍
- 药理学 药理学是指药理学的学科.
背景情况:
- 抑郁症缺乏足够的新型治疗策略.
- 异常的大脑生物能代谢是抑郁症潜在的神经生物学基础.
- 内源子显示神经保护潜力,可以增强大脑的生物能量.
研究的目的:
- 探索SGLT2抑制剂可以治疗抑郁症的假设.
- 为了研究SGLT2抑制剂诱导的生成在情绪改善中的作用.
主要方法:
- 对SGLT2抑制剂和生成现有研究的综述.
- 基于人群的研究分析,将SGLT2抑制剂与情绪改善联系起来.
- 突出SGLT2抑制剂作为潜在的抑郁症治疗的理由.
主要成果:
- 用于糖尿病的SGLT2抑制剂诱导生成.
- 人口研究将SGLT2抑制剂与情绪改善联系在一起.
- 生成可能会增强大脑能量代谢,并提供情绪益处.
结论:
- 由SGLT2抑制剂诱导的生成为抑郁症提供了一个新的治疗标.
- 这种方法通过准大脑生物能量来提供一种替代的治疗策略.
- 需要进一步的研究来验证SGLT2抑制剂对抑郁症的治疗.
更多相关视频
相关概念视频
Secondary Active Transport
121.5K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
121.5K
Antidepressant Drugs: MAOIs and Other Agents
275
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
275
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
208
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
208
Oral Hypoglycemic Agents: Biguanides and Glitazones
236
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
236
Dipeptidyl Peptidase 4 Inhibitors
214
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
214
Glucose Transporters
23.2K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
23.2K


